Adams execs
This article was originally published in The Tan Sheet
Executive Summary
Helmut Albrecht, MD, joins Adams Respiratory Therapeutics to serve as senior VP-R&D, the firm announces Oct. 29. Albrecht will oversee all R&D activities, including clinical development, regulatory issues and new product development; the new exec said Adams "is ready to expand its presence in the respiratory category." Most recently, Albrecht was Novartis Consumer Health/OTC business unit's VP-global preclinical & clinical development. New VP-Regulatory Affairs Susan Witham will report to Albrecht. Witham previously held senior positions at J&J Consumer and Novartis. The appointments follow Adams' recently announced strategic decision to focus on OTCs and expand the Mucinex line (1"The Tan Sheet" May 31, 2004, p. 9)...
You may also be interested in...
Mucinex Line Extensions Underscore Adams’ Commitment To Building OTCs
A major task facing Adams Respiratory Therapeutics' new VP-OTC Marketing & Business Development Robert Casale will be to plan a Fall 2004 launch of extensions to the firm's Mucinex expectorant brand
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.